A critical limitation for successful management of small intestinal neuroendocrine tumors (SINETs) is early disease detection and identification of progression. Up to 50% of SINETs are metastatic at diagnosis, usually involving the liver (1) . This reflects three issues. First, tumors are covert until hormonal (carcinoid) symptoms develop, which occurs after hepatic metastasis (in 30% to 40% of cases) (2) . Second, biomarkers such as chromogranin A (CgA) have limited clinical utility, and third, imaging has identification limitations (3). CgA is compromised by numerous nonclinical conditions that elevate it (e.g., renal failure, use of proton-pump inhibitors), variability of assays, and false-negative results (3). There is also major disagreement regarding its use per National Comprehensive Cancer Network guidelines (category 3 biomarker) (2) . Imaging and Response Evaluation Criteria in Solid Tumors likewise are well known to be limited (3) . Up to ;70% of SINETs are estimated to be understaged by imaging (4) . Histopathological examination reveals tumor deposits in .50% of resected specimens not detected by imaging (1, 5) . Given this, standard strategies fail to detect progressive disease early, and appropriate therapy is delayed.
Liquid biopsy has considerable utility in other cancers and has recently been developed for neuroendocrine tumors (NETs; NETest) (6, 7) . The strategy involves measuring circulating tumor RNA with high sensitivity and specificity. It can be repeated regularly (blood sample), and "omic" analyses yield real-time information regarding tumor behavior (6) . It has been suggested that this will replace conventional monoanalyte biomarkers, which measure tumor secretory status and provide no information about the biological behavior of a cancer (3).
The NETest was derived from tumor transcriptomebased analysis and is an algorithmic evaluation of 51 neuroendocrine gene transcripts, representative of eight core drivers of neuroendocrine tumorigenesis: SSTRome, proliferome, metabolome, secretome, epigenome, growth factor signalome, plurome, and apoptome (6) . PCR amplifications of genes isolated from peripheral blood are measured and scored to define disease activity (0% to 100%) (20%: upper limit of normal; 21% to 40%: low; 41% to 79%: moderate; $80%: high) (8) . The test accurately detects NETs (.90%) and identifies progressive disease, completeness of surgical resection, and therapeutic responsiveness [e.g., somatostatin analogues (SSAs)] (8).
We present a case in which blood molecular testing in the presence of normal blood CgA and negative 68 Gallium ( 68 Ga) positron emission tomography (PET) ( Fig. 1 ; Table 1 ) identified biopsy-proven micrometastatic hepatic neuroendocrine disease. Informed consent was obtained from the patient.
Case Description
A 52-year-old woman presented in August 2013 with altered bowel movements and abdominal pain. CT enterography depicted wall thickening in the distal ileum/ proximal cecum [ Fig. 2(a) ]. This was considered Crohn and NETest scores are presented as fold-change (FC; above the upper limit of normal). Background color shows biomarker level ranges: green, normal range (#1 FC, representing NETest scores from 0% to 20%); faded pink, elevated biomarker levels .1 to 4 FC (.1 to 4 FC range for the NETest represents the score range of 21% to 79% and low to moderate disease activity); red, $4 FC elevation of biomarker levels (NETest score $80%, corresponding with highly biologically active/ progressive disease). Derivation of the NETest score: The test uses a two-step protocol (mRNA isolation, cDNA production, and PCR) from EDTAcollected whole blood. Blood gene expression of the 51 NET-specific markers (representative for all eight neuroendocrine tumorigenesis driver clusters) is normalized to a housekeeper gene and quantified vs a population control. Gene expression levels are related to an outcome based on four machine learning algorithms. The algorithmic output of these analyses enables the test to differentiate NET disease from controls and stable disease from progressive disease. To facilitate the clinical use of this information, the diagnostic score is represented as a correlate of clinical activity. Upper limit of normal is 20%; low disease activity (stable disease) is 21% to 40%; moderate activity is 41% to 79%, and high disease activity is $80%. Asterisk (*) indicates negative for NET. PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analogue (lanreotide).
disease. At colonoscopy, a large ulcerated, friable mass obstructing the ileocecal valve was noted [ Fig. 2 On January 2017, symptomatic cholelithiasis prompted a cholecystectomy. The abdomen was normal, but random multiple peritoneal and core needle biopsies from segment VI were performed. The latter revealed foci of a metastatic tumor of ;3 mm (microscopic measurement; no mitotic figures were evident, and the tumor was too small for accurate Ki-67 assessment) [ Fig. 2(c) ]; peritoneal biopsies were negative. SSA was resumed (lanreotide depot 60 mg monthly), and the NETest in February 2017 was low (20%). In July 2017, the NETest was elevated (73%), but MRI was unremarkable. SSA was increased to 120 mg monthly, but NETest levels remained elevated throughout: September 2017 (73%) and March 2018 (87%). Followup 68 Ga-DOTA-TATE PET/CT (January 2018) and 68 Ga-DOTA-TATE PET/MRI (July 2018) [ Fig. 2(d) ] were both negative. The NETest in May 2018 remained elevated but low (27%).
The patient remains on SSA. Over this entire 5-year period, CgA and pancreastatin levels remained within the normal range. Blood serotonin levels fluctuated 1.1 6 0.18 upper limit of normal (Fig. 1) , whereas urinary 5-hydroxyindoleacetic acid measurement was undertaken once and was normal.
Discussion
A critical clinical problem after resection is the identification of minimal residual NET disease and characterization of its biological likelihood to progress. In this report, we demonstrated the sensitivity of the NETest for the identification of image-negative (CT, MRI, and 68 Ga PET) and biomarker-negative disease (CgA, pancreastatin, serotonin) in the presence of micrometastatic liver disease. Needle biopsy histology confirmed the blood molecular measurement. Repeated utilization of diverse imaging modalities (e.g., CT, MRI, and 68 Ga PET/CT) failed to identify postoperative disease. Similarly, standard biomarkers failed to detect micrometastatic liver disease or disease progression. Liver metastatic disease is an important prognostic factor in SINET; early detection facilitates and improves survival (1). For imaging, spatial resolution of 2 to 4 mm (CT/MRI) and 4 to 6 mm ( 68 Ga-SSA PET/CT or 18 Ffludeoxyglucose PET/CT) (9) infers delay in tumor detection. A 10-mm lesion is well known to exhibit at least an ;10 9 cell bulk, whereas circulating NET genes can be identified in as few as one tumor cell/mL (8) . Micrometastatic disease is therefore far more likely to be identified by molecular amplification (gene expression-PCR) techniques than by imaging alone. Consistent with this observation are reports of the effectiveness of molecular techniques (PCR based) in SINET lymph nodes considered negative at immunohistochemistry (10) . In 50% of histology-negative nodes, CgA transcripts (mRNA) were identifiable by PCR (10). Liver lesions have been identified in .50% of image-negative hepatic disease cases postoperatively (1, 5) . In 54% of these cases, the size was #2 mm (5). The failure of anatomical or somatostatin receptor-based imaging to identify hepatic micrometastases (#2 mm) is problematic in early detection (1) . The real incidence of metastatic liver disease is likely much higher than reported. A molecular tool would therefore be of considerable utility in early identification of disease.
The presence of undetected hepatic micrometastases in SINETs would explain the clinical observation of frequent tumor recurrence following R0 primary resection or hepatic resection. In one study, 11 of 25 patients with an NET (44%) with intrahepatic recurrence after R0 hepatectomy exhibited hepatic micrometastases; no micrometastases were identified in seven who remained disease-free after surgical resection (1) . This report demonstrates that hepatic micrometastases can be identified by the measurement of NET genes in blood. Overall, these observations support the consideration of adjuvant treatment in NET disease. In this patient, CgA was never elevated, irrespective of disease stage, alterations in disease activity, or various treatments (e.g., SSA or PRRT). Similarly, pancreastatin (CgA derivative), an alternative biomarker, was of no value. Circulating serotonin and its urinary metabolite 5-hydroxyindoleacetic acid, indicators of tumor secretory status, were also not useful in defining disease. In contrast, a 51-gene NET-specific gene panel identified disease presence and progress despite repeated negative anatomical and functional imaging.
Conclusions
Use of a circulating gene expression biomarker is a novel strategy to optimize early disease detection. A liquid biopsy, requiring only venipuncture, is a viable strategy Ga-DOTA-TATE PET/MRI scan (July 2018) is disease-negative, with a large cyst in liver segment VI.
for monitoring the efficacy of treatment and progression of NET disease and provides a useful tool to minimize repetitive exposure to imaging. A prospective clinical trial that includes patients who are image-negative but NETestpositive would be of value to demonstrate the clinical utility of the liquid biopsy.
